NICE recommends several treatment options to help thousands with moderate rheumatoid arthritis
Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today
-
NICE draft guidance does not recommend risdiplam for treating spinal muscular atrophy
NICE has today (2 June 2021) published draft guidance for public consultation which does not recommend risdiplam (also called Evrysdi and made by Roche) for treating the rare genetic disorder spinal muscular atrophy (SMA).
-
NICE updates recommendations for two COVID-19 therapeutics
NICE has updated its advice on two therapeutics for managing COVID-19 – remdesivir and colchicine.
-
NICE urges further research on the safety and efficacy of two procedures to treat conditions affecting women
The long-term safety and efficacy is inadequate on two procedures NICE is calling for further evidence on
